An Adjuvant Vaccination With Reniale Prolongs Survival In Patients With Renal Cell Carcinoma Following Radical Nephrectomy

UroToday - The authors presented at the annual meeting of the AUA, a secondary analysis on their previously published work with the tumor vaccine Reniale (made from tumor lysate) in the adjuvant setting for patients at high risk of relapse following surgery. This secondary ITT analysis was performed on 477 patients (233 in the Reniale group and 244 in the control group) The authors found that there was a significant improvement in recurrence free survival but not overall survival in the group that received Reniale in the adjuvant setting. In a smaller subgroup of patients treated "per protocol", there was a statistically significant benefit in both RFS and OS for the Reniale group as compared to control.


Doehn C, et al., Germany


Reported by UroToday Contributing Editor Christopher G. Wood, MD, FACS


UroToday - the only urology website with original content global urology key opinion leaders actively engaged in clinical practice.


To access the latest urology news releases from UroToday, go to:
www.urotoday


----------------------------
Copyright © 2007 - UroToday
Reproduced for blog with permission of UroToday.
----------------------------


Buy Urispas Without Prescription